Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The cAMP-dependent protein kinase catalytic subunit (PKAc) is the enzymatic component of the Protein Kinase A (PKA) holoenzyme, a central mediator of the second messenger cyclic AMP (cAMP) signaling pathway (StatPearls, PMID: 30252315). In its inactive state, PKAc is sequestered by regulatory subunits; upon cAMP binding to these subunits, PKAc is released to phosphorylate a wide array of substrate proteins on serine and threonine residues. This phosphorylation regulates diverse cellular processes, including glucose and lipid metabolism, gene transcription via CREB, and ion channel activity (UniProt, P17612). Dysregulation of PKAc is linked to various pathologies, most notably through gain-of-function mutations or gene fusions. For instance, the DNAJB1-PRKACA fusion is a hallmark of fibrolamellar hepatocellular carcinoma, while somatic mutations like L206R are frequently found in adrenal tumors causing Cushing's syndrome (PubMed, PMID: 24523430; PMID: 24572368). While PKAc is a critical therapeutic target, its ubiquitous expression and involvement in fundamental physiological processes present significant challenges for achieving selective inhibition without systemic toxicity. Current drug discovery efforts are focused on identifying isoform-specific inhibitors or targeting the unique protein-protein interfaces created by oncogenic fusions.
PKAc functions as a serine/threonine kinase that phosphorylates substrates containing the consensus motif Arg-Arg-X-Ser/Thr, following its release from the PKA regulatory subunits upon cAMP binding (UniProt, P17612; StatPearls, PMID: 30252315).
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on cAMP-dependent protein kinase catalytic subunit (PKAc) (PKAc).